Ying-Ju Lai
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Ying-Ju Lai has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
- Li-Ju Wang
UPMC Hillman Cancer Center, University of Pittsburgh, 5115 Centre Ave, Pittsburgh, PA, 15232, USA
42 shared publications - Yu-Chiao Chiu
Department of Medicine, University of Pittsburgh School of Medicine , Pittsburgh, PA
42 shared publications - Arun Das
Cancer Virology Program, UPMC Hillman Cancer Center, Pittsburgh, PA, USA
41 shared publications - Chien-Hung Shih
UPMC Hillman Cancer Center, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania
41 shared publications - George C. Tseng
Department of Biostatistics, University of Pittsburgh, Pittsburgh, USA
41 shared publications - Hugh Galloway
UPMC Hillman Cancer Center, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania
41 shared publications
Latest Publications
- Open Access
- 2 February 2026
- Published by Elsevier in Cancer Letters
- Vol. 642, 218289
High-throughput drug screening for targeting polyploid cancer cells with an interactive web portal
- 2 February 2026
- Published by Elsevier in Cancer Letters
- Vol. 642, 218289
Open AccessHigh-throughput drug screening for targeting polyploid cancer cells with an interactive web portal
- Open Access
- 13 May 2025
- Published by American Association for Cancer Research (AACR)
Table S7 from Inferring Drug–Gene Relationships in Cancer Using Literature-Augmented Large Language Models
Table S7 from Inferring Drug–Gene Relationships in Cancer Using Literature-Augmented Large Language Models
- 13 May 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S7 from Inferring Drug–Gene Relationships in Cancer Using Literature-Augmented Large Language Models
Table S7 from Inferring Drug–Gene Relationships in Cancer Using Literature-Augmented Large Language Models
- Open Access
- 13 May 2025
- Published by American Association for Cancer Research (AACR)
Figure 4 from Inferring Drug–Gene Relationships in Cancer Using Literature-Augmented Large Language Models
Drug–target network in liver cancer. A, Drug–target network in liver cancer. The network was constructed by extracting drug–gene pairs associated with liver cancer from Fig. 3A, in which liver cancer was identified as a primary cancer type among multiple possible types generated through GPT-4o inference. The node size and font size are proportional to the degree (i.e., the number of connections). Drugs and genes discussed in the main text are highlighted in bold. B, Kaplan–Meier curves for progression-free survival of patients with HCC, the major type of liver cancer, treated with sorafenib in the IMBrave150 clinical trial, comparing CTNNB1-mutated (CTNNB1-Mut; n = 19) and CTNNB1 wild-type patients (CTNNB1-WT; n = 26). Statistical significance was assessed by the log-rank test. C, Boxplots showing differential sensitivity to sorafenib between CTNNB1-mutated (CTNNB1-Mut; n = 2) and CTNNB1 wild-type liver cancer cell lines (CTNNB1-WT; n = 18). Drug sensitivity data are represented as the log2 fold change in cell counts following treatment, derived from the Profiling Relative Inhibition Simultaneously in Mixtures (PRISM) drug screening project. Statistical significance was assessed by the one-tailed Mann–Whitney U test. D, Correlation between CTNNB1 genetic dependency (represented by the Chronos gene-effect score from DepMap) and sorafenib sensitivity (PRISM) in liver cancer cell lines (n = 18). A more negative gene-effect score represents a stronger genetic dependency. The names of cell lines exhibiting strong dependency on CTNNB1 (with gene-effect scores < −1) are labeled.
- 13 May 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 4 from Inferring Drug–Gene Relationships in Cancer Using Literature-Augmented Large Language Models
Drug–target network in liver cancer. A, Drug–target network in liver cancer. The network was constructed by extracting drug–gene pairs associated with liver cancer from Fig. 3A, in which liver cancer was identified as a primary cancer type among multiple possible types generated through GPT-4o inference. The node size and font size are proportional to the degree (i.e., the number of connections). Drugs and genes discussed in the main text are highlighted in bold. B, Kaplan–Meier curves for progression-free survival of patients with HCC, the major type of liver cancer, treated with sorafenib in the IMBrave150 clinical trial, comparing CTNNB1-mutated (CTNNB1-Mut; n = 19) and CTNNB1 wild-type patients (CTNNB1-WT; n = 26). Statistical significance was assessed by the log-rank test. C, Boxplots showing differential sensitivity to sorafenib between CTNNB1-mutated (CTNNB1-Mut; n = 2) and CTNNB1 wild-type liver cancer cell lines (CTNNB1-WT; n = 18). Drug sensitivity data are represented as the log2 fold change in cell counts following treatment, derived from the Profiling Relative Inhibition Simultaneously in Mixtures (PRISM) drug screening project. Statistical significance was assessed by the one-tailed Mann–Whitney U test. D, Correlation between CTNNB1 genetic dependency (represented by the Chronos gene-effect score from DepMap) and sorafenib sensitivity (PRISM) in liver cancer cell lines (n = 18). A more negative gene-effect score represents a stronger genetic dependency. The names of cell lines exhibiting strong dependency on CTNNB1 (with gene-effect scores < −1) are labeled.
- Open Access
- 13 May 2025
- Published by American Association for Cancer Research (AACR)
Table S7 from Inferring Drug–Gene Relationships in Cancer Using Literature-Augmented Large Language Models
Table S7 from Inferring Drug–Gene Relationships in Cancer Using Literature-Augmented Large Language Models
- 13 May 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S7 from Inferring Drug–Gene Relationships in Cancer Using Literature-Augmented Large Language Models
Table S7 from Inferring Drug–Gene Relationships in Cancer Using Literature-Augmented Large Language Models